Please provide your email address to receive an email when new articles are posted on . Rademikibart improved lung function and asthma control in adults with moderate to severe persistent asthma. The ...

Low-dose ICS remain essential for every asthma patient, and GINA/CFA guidance favors phenotype-tailored step-up strategies ...

Please provide your email address to receive an email when new articles are posted on . Rademikibart led to better lung function and asthma control in adults with moderate to severe persistent asthma ...

For patients with moderate to severe eosinophilic asthma or oral corticosteroid (OCS)-dependent asthma and inadequate disease control, the decision to add biologic therapy is based on the patient’s ...

The ability of four different asthma assessment tools to predict each of five adverse clinical asthma outcomes was modeled using both logistic regression and CART analysis using data collected for non ...

The update includes new focus on monitoring asthma control as the goal for asthma therapy and distinguishing between classifying asthma severity and monitoring asthma control Emphasis is placed on ...

On May 5, 2025, the Global Initiative For Asthma (GINA) published the 2026 update to their Global Strategy for Asthma ...

Adolescents with overweight or obesity and asthma taking a GLP-1 agent had less risk of asthma exacerbations compared with controls. Teens on a GLP-1 agent also were less likely to need systemic ...

Despite a wealth of available treatments to control the symptoms of chronic asthma, the lung disease has no cure. The discovery of an unexpected cause of asthma could change that. A glitch in the ...